Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

29%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

6 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
9(56.3%)
Phase 3
5(31.3%)
Phase 1
2(12.5%)
16Total
Phase 2(9)
Phase 3(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT07505004Phase 3Recruiting

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Role: lead

NCT05818553Phase 2Active Not Recruiting

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Role: lead

NCT07010471Phase 3Recruiting

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

Role: lead

NCT07287163Phase 3Enrolling By Invitation

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Role: lead

NCT07019922Phase 3Recruiting

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

Role: lead

NCT06087276Phase 3Enrolling By Invitation

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Role: lead

NCT05737784Phase 1Recruiting

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Role: lead

NCT06999902Phase 2Recruiting

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

Role: lead

NCT06908356Phase 2Recruiting

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

Role: lead

NCT06840925Phase 1Not Yet Recruiting

A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628

Role: lead

NCT05021991Phase 2Completed

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

Role: lead

NCT05021978Phase 2Completed

A Clinical Trial of PRAX-944 in Participants With Essential Tremor

Role: lead

NCT05407727Completed

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

Role: lead

NCT05260541Phase 2Terminated

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Role: lead

NCT05387642Phase 2Withdrawn

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

Role: lead

NCT04969510Phase 2Completed

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

Role: lead

NCT04832425Phase 2Completed

A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

Role: lead

All 17 trials loaded